Key Drivers
- Elite margins
- Debt-free balance sheet
- Rich valuation
AIAI Summary
UTHR has shifted from a straightforward quality biotech story to a “prove the next growth leg” investment: its elite margins, cash flow, and balance sheet can absorb setbacks, but the stock likely stays capped unless Tyvaso weakness is clearly offset by pipeline/regulatory wins that re-accelerate revenue.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Elite margins
- •Debt-free balance sheet
- •Rich valuation
UTHR combines elite margins, strong cash flow, and a debt-free balance sheet, but its high multiples and SBC make the stock high-quality yet richly valued.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •$500 support
- •Failed rebound
UTHR remains in a cautious downtrend, with $500 acting as key support, $530–$540 as resistance, and fading momentum after a brief rebound suggesting downside risk unless it reclaims resistance.
Brief rebound from $516.31 to $538.84 quickly reversed into lower closes
Sentiment & News
Key News Insights:
- •TYVASO Pressure
- •Ralinepag Data
- •NDA Progress
United Therapeutics beat EPS on Q2 results and advanced a promising PAH pipeline, but softer TYVASO sales and mixed ownership signals keep near-term growth and competitive pressure in focus.
The stock impact is likely mixed, with pipeline and regulatory progress supporting the long term while near-term sales weakness limits upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings